Semaglutide 7.2 Mg In Obesity: Step Up Trial Readout
Key Takeaways
- Semaglutide 7.2 mg was associated with greater week 72 weight loss than semaglutide 2.4 mg and placebo.
- Higher-dose treatment was also associated with more participants reaching larger weight-loss thresholds and with reduced waist circumference versus placebo.
- Gastrointestinal adverse events and dysaesthesia were more common with 7.2 mg, serious adverse events occurred in all groups, and the investigators described the overall risk-benefit profile favorably.
The STEP UP trial was a phase 3b, randomized, double-blind, placebo-controlled and active-controlled study conducted across 95 hospitals, specialist clinics, and medical centers in 11 countries. Adults with BMI 30 kg/m2 or greater and no diabetes were assigned 5:1:1 to once-weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo, all with lifestyle intervention, for 72 weeks. The randomized sample included 1407 participants, with 1005, 201, and 201 in the respective groups. Women accounted for 73.7% of participants; mean age was 47 years, mean bodyweight was 113.0 kg, and mean BMI was 39.9 kg/m2. Coprimary endpoints were percentage change in bodyweight and the proportion achieving at least 5% bodyweight reduction for semaglutide 7.2 mg versus placebo at week 72.
At week 72, mean bodyweight change was -18.7% with semaglutide 7.2 mg, -15.6% with semaglutide 2.4 mg, and -3.9% with placebo. The estimated treatment difference for 7.2 mg versus 2.4 mg was -3.1% with a 95% CI of -4.7 to -1.6. The estimated treatment difference for 7.2 mg versus placebo was -14.8%, with a 95% CI of -16.2 to -13.4. Both comparisons had p values below 0.0001. The higher dose separated from both comparator groups on the primary weight-loss outcome.
Secondary efficacy measures followed the same pattern. Semaglutide 7.2 mg increased the odds of reaching 5%, 10%, 15%, 20%, and 25% bodyweight reduction versus placebo. The odds ratio for at least 5% weight loss versus placebo was 12.1, with a 95% CI of 8.3 to 17.6 and p<0.0001. Compared with semaglutide 2.4 mg, the 7.2 mg dose was also superior at the 20% threshold, with an odds ratio of 1.8, and at the 25% threshold, with an odds ratio of 2.4. Waist circumference also improved versus placebo, with an estimated treatment difference of -11.7 cm, a 95% CI of -13.0 to -10.4, and p<0.0001. These findings were consistent with the primary efficacy results.
Gastrointestinal adverse events were more common with semaglutide 7.2 mg than with semaglutide 2.4 mg or placebo. The rates were 70.8%, 61.2%, and 42.8%, respectively. Dysaesthesia was also more common with the higher dose, occurring in 22.9%, 6.0%, and 0.5% of participants across the three groups. Serious adverse events occurred in all groups, affecting 6.8% with semaglutide 7.2 mg, 10.9% with semaglutide 2.4 mg, and 5.5% with placebo. The investigators concluded that semaglutide 7.2 mg was superior to placebo and 2.4 mg for bodyweight reduction while retaining a favorable risk-benefit profile.
Frequently Asked Questions
What's the latest on GLP-1 receptor agonists for obesity and weight management?
The STEP UP phase 3b trial tested once-weekly semaglutide 7.2 mg in 1,407 adults with BMI ≥30 kg/m² and no diabetes, randomized 5:1:1 to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo for 72 weeks alongside lifestyle intervention. Mean body-weight change at week 72 was −18.7% with semaglutide 7.2 mg versus −15.6% with semaglutide 2.4 mg and −3.9% with placebo. The estimated treatment difference for 7.2 mg versus placebo was −14.8% (95% CI −16.2 to −13.4), and for 7.2 mg versus 2.4 mg was −3.1% (95% CI −4.7 to −1.6); both p<0.0001.
What's new in obesity medicine for primary care?
Higher-dose semaglutide expands the menu of effective options. In STEP UP, semaglutide 7.2 mg increased the odds of reaching ≥5% body-weight reduction versus placebo (OR 12.1; 95% CI 8.3–17.6; p<0.0001) and was also superior to semaglutide 2.4 mg at the ≥20% threshold (OR 1.8) and the ≥25% threshold (OR 2.4). Waist circumference improved by an estimated 11.7 cm versus placebo. For primary care clinicians weighing intensification of GLP-1 receptor agonist therapy, these data support a dose–response benefit in body weight in adults with obesity and no diabetes, with a different tolerability profile at the higher dose.
Where can I find CME on GLP-1 prescribing for non-diabetic obesity?
ReachMD's Advances in Obesity Management Learning Center hosts free, accredited CME on GLP-1 receptor agonist prescribing in adults with obesity who do not have diabetes, including dose selection, escalation, monitoring, and adverse-event management. The Endocrinology CME hub aggregates additional accredited education on the broader incretin class. Both are free after a no-cost ReachMD registration: Advances in Obesity Management and Endocrinology CME.
What were the safety findings for semaglutide 7.2 mg in STEP UP?
Gastrointestinal adverse events were more frequent with semaglutide 7.2 mg than with 2.4 mg or placebo: 70.8%, 61.2%, and 42.8%, respectively. Dysaesthesia was also more common with the higher dose, occurring in 22.9%, 6.0%, and 0.5% across the three groups. Serious adverse events occurred in 6.8% of the 7.2 mg group, 10.9% of the 2.4 mg group, and 5.5% of the placebo group. The investigators concluded that semaglutide 7.2 mg was superior to placebo and to 2.4 mg for body-weight reduction while retaining what they described as a favorable risk-benefit profile.
Who do the STEP UP findings apply to — and where are they limited?
STEP UP enrolled adults with BMI ≥30 kg/m² and no diabetes; women accounted for 73.7% of participants, mean age was 47 years, mean body weight was 113.0 kg, and mean BMI was 39.9 kg/m². The trial was conducted across 95 sites in 11 countries. Applicability to adults with type 2 diabetes, adults below this BMI threshold, or longer-term outcomes beyond 72 weeks is not established by this analysis. STEP UP is one component of a broader semaglutide 7.2 mg program; STEP UP T2D evaluated the same dose in adults with obesity and type 2 diabetes and is reported separately.